Quality Management for Point-Of-Care Testing of Pathogen Nucleic Acids: Chinese Expert Consensus
- PMID: 34722341
- PMCID: PMC8548827
- DOI: 10.3389/fcimb.2021.755508
Quality Management for Point-Of-Care Testing of Pathogen Nucleic Acids: Chinese Expert Consensus
Abstract
COVID-19 continues to circulate globally in 2021, while under the precise policy implementation of China's public health system, the epidemic was quickly controlled, and society and the economy have recovered. During the pandemic response, nucleic acid detection of SARS-CoV-2 has played an indispensable role in the first line of defence. In the cases of emergency operations or patients presenting at fever clinics, nucleic acid detection is required to be performed and reported quickly. Therefore, nucleic acid point-of-care testing (POCT) technology for SARS-CoV-2 identification has emerged, and has been widely carried out at all levels of medical institutions. SARS-CoV-2 POCT has served as a complementary test to conventional polymerase chain reaction (PCR) batch tests, thus forming an experimental diagnosis platform that not only guarantees medical safety but also improves quality services. However, in view of the complexity of molecular diagnosis and the biosafety requirements involved, pathogen nucleic acid POCT is different from traditional blood-based physical and chemical index detection. No guidelines currently exist for POCT quality management, and there have been inconsistencies documented in practical operation. Therefore, Shanghai Society of Molecular Diagnostics, Shanghai Society of Laboratory Medicine, Clinical Microbiology Division of Shanghai Society of Microbiology and Shanghai Center for Clinical Laboratory have cooperated with experts in laboratory medicine to generate the present expert consensus. Based on the current spectrum of major infectious diseases in China, the whole-process operation management of pathogen POCT, including its application scenarios, biosafety management, personnel qualification, performance verification, quality control, and result reporting, are described here. This expert consensus will aid in promoting the rational application and robust development of this technology in public health defence and hospital infection management.
Keywords: expert consensus; nucleic acid; pathogen; point-of-care testing; whole-process operation management.
Copyright © 2021 Mo, Wang, Zhu, Yu, Chang, Zhang, Li, Sun, Zhou, Xu, Zhang, Gao, Guan, Xiao and Wu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Canadian Society of Clinical Chemists (CSCC) consensus guidance for testing, selection and quality management of SARS-CoV-2 point-of-care tests.Clin Biochem. 2021 Sep;95:1-12. doi: 10.1016/j.clinbiochem.2021.05.010. Epub 2021 May 25. Clin Biochem. 2021. PMID: 34048776 Free PMC article. Review.
-
Point of care molecular and antigen detection tests for COVID-19: current status and future prospects.Expert Rev Mol Diagn. 2022 Aug;22(8):797-809. doi: 10.1080/14737159.2022.2122712. Epub 2022 Sep 14. Expert Rev Mol Diagn. 2022. PMID: 36093682 Review.
-
Chinese Expert Consensus on the Nucleic Acid Detection of SARS-CoV-2.Ann Transl Med. 2020 Dec;8(24):1631. doi: 10.21037/atm-20-4060. Ann Transl Med. 2020. PMID: 33490143 Free PMC article. Review.
-
[Expert consensus on traditional Chinese medicine health management in adults with SARS-CoV-2 variant infection at home].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Dec;34(12):1233-1237. doi: 10.3760/cma.j.cn121430-20221210-01079. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36567574 Chinese.
-
Application experience of a rapid nucleic acid detection system for COVID-19.Microbes Infect. 2022 Jun;24(4):104945. doi: 10.1016/j.micinf.2022.104945. Epub 2022 Jan 31. Microbes Infect. 2022. PMID: 35093551 Free PMC article.
Cited by
-
Influence on emergency digit replantation and outcome assessment after COVID-19 virus nucleic acid testing normalization.Front Surg. 2023 Jan 6;9:1078933. doi: 10.3389/fsurg.2022.1078933. eCollection 2022. Front Surg. 2023. PMID: 36684330 Free PMC article.
-
Point-of-care testing in companion and food animal disease diagnostics.Front Vet Sci. 2022 Nov 25;9:1056440. doi: 10.3389/fvets.2022.1056440. eCollection 2022. Front Vet Sci. 2022. PMID: 36504865 Free PMC article. Review.
-
Correlation between the gut microbiota characteristics of hosts with severe acute pancreatitis and secondary intra-abdominal infection.Front Med (Lausanne). 2024 Aug 21;11:1409409. doi: 10.3389/fmed.2024.1409409. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39234039 Free PMC article.
-
Editorial: Progressing the understanding and management of bloodstream infections.Front Med (Lausanne). 2025 Feb 4;12:1562934. doi: 10.3389/fmed.2025.1562934. eCollection 2025. Front Med (Lausanne). 2025. PMID: 39967598 Free PMC article. No abstract available.
-
CRISPR/Cas12a and recombinase polymerase amplification-based rapid on-site nucleic acid detection of duck circovirus.Virol J. 2024 Dec 19;21(1):322. doi: 10.1186/s12985-024-02577-7. Virol J. 2024. PMID: 39702333 Free PMC article.
References
-
- Centers for Disease Control and Prevention (U.S.) (2015). Center for Surveillance, Epidemiology, and Laboratory Services, Division of Laboratory Systems, Centers for Medicare & Medicaid Services (U.S.). Developing an Individualized Quality Control Plan: A Step-by-Step Guide.
-
- Clinical and Laboratory Standards Institute (2018). Validation and Verification of Multiplex Nucleic Acid Assays, 2nd Edition. MM17.
-
- Health Industry Standard of the People's Republic of China (2017). General Biosafety Standard for Causative Bacteria Laboratories (WS 233-2017).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous